openPR Logo
Press release

Easy Availability and Better Efficacy are Expected to Drive the Global Paclitaxel Injection Market

10-18-2016 09:42 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Easy Availability and Better Efficacy are Expected to Drive

Paclitaxel injection is a viscous anticancer drug, derived from the bark of the Pacific yew tree. Paclitaxel belongs to the group of drugs called antineoplastic. Paclitaxel injection is primarily used to treat various advanced stage cancer of the breast,ovaries, Kaposi sarcoma and non-small cell lung cancer. It is type of cytoskeletal medication that targets tubulin, which are a type of globular proteins.

Download Exclusive Sample of this Report: http://bit.ly/2e1vyo3

The body cells that have defects in chromosome segregation, mitotic spindle assembly and cell division are treated Paclitaxel. Paclitaxel works by inhibiting the growth of cancer cells and by stabilizing the microtubule polymer. Paclitaxel injection should be administered under the supervision of an oncologists with experience in chemotherapy.

Paclitaxel injection is used against some of the majormedical conditions-

-Bladder cancer

-Esophageal cancer

-Cervical cancer

-Endometrial cancer

-Throat cancer

-Non-small cell lung cancer

-Kaposi's sarcoma

-Stomach cancer

-Testicular cancer

-Fallopian tube cancer

Advantages of Paclitaxel injection such as immediate results, easy availability and better efficacy are some of the factors that are expected to drive the global Paclitaxel injection market. However, adverse effects such as allergy, leucopenia, blood clots, fever, diarrhea and weight loss are few drawbacksthat could hinder the growth of global Paclitaxel injection market. Moreover, stringent regulatory procedure could also act as the hindrance for the global market.

In the geographical perspective, North America is the largest market for Paclitaxel injection owing to the high incidence and prevalence rate of various cancers. The Asian-Pacific and European region arealso expected to be a potential markets for Paclitaxel injection owing to the increased number of cases of advanced stage cancer patients.

Browse Research Report: http://bit.ly/2e3ygMc

The companies involved in development and manufacturing of Paclitaxel injection are AbraxisBioScience Inc., Abbott Laboratories, Bristol-Myers Squibb, Fresenius Kabi Oncology Ltd., Onco Therapies Ltd., Strides Arcolab Ltd., Sagent Pharmaceuticals Inc. and Novasep, amongst others.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Easy Availability and Better Efficacy are Expected to Drive the Global Paclitaxel Injection Market here

News-ID: 373530 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Paclitaxel

Major Force in the Paclitaxel Injection Market 2025: Rising Incidence Of Breast …
How Will the Paclitaxel Injection Market Grow, and What Is the Projected Market Size? The paclitaxel injection market has seen rapid growth in recent years. It will increase from $6.02 billion in 2024 to $6.87 billion in 2025, at a CAGR of 14.1%. This growth is driven by clinical research, the rising incidence of cancer, greater patient awareness and education, and the globalization of the pharmaceutical industry. The paclitaxel injection market is
Paclitaxel Injection Global Market Report 2024 - Paclitaxel Injection Market Sha …
"The Business Research Company recently released a comprehensive report on the Global Paclitaxel Injection Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The paclitaxel injection
Global Albumin-bound Paclitaxel Market |Bound for Success: Navigating the Global …
Global Albumin-bound Paclitaxel Market Overview The Albumin-bound Paclitaxel market is a dynamic and multifaceted landscape that encompasses various products, services, and industries. It is characterized by intense competition, rapid innovation, changing consumer behavior, and evolving market trends. Businesses operating in the Albumin-bound Paclitaxel market need to have a deep understanding of the market dynamics, including its size, growth rate, customer preferences, competitive landscape, and regulatory environment. Market research reports providing a comprehensive
Paclitaxel HPLC Global Market Research Report 2025
Paclitaxel HPLC Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-chemical/paclitaxel-hplc-market/81094 The report firstly introduced the Paclitaxel HPLC basics: definitions, classifications, applications and market
Paclitaxel Global Market Research Report 2025
Paclitaxel Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/paclitaxel-market-3/81092 The report firstly introduced the Paclitaxel basics: definitions, classifications, applications and market overview; product
Global Paclitaxel Market Research Report 2017: Novasep, Samyang
In this report, the global Paclitaxel market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Paclitaxel in these regions, from 2012 to 2022 (forecast), covering North America Europe China Japan Southeast Asia India Fill